Davelyne Hines
Family Medicine · Thomasville, GANPI 1073162004
Payments from drug & device makers
Across 83 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$632
- Novo Nordisk$270
- AbbVie$247
- Pfizer$172
- Almatica Pharma LLC$134
- Corium, LLC$93
- plus $462 from 19 others
What the payments were for
- Food & beverage$2,009100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 9 | $632 |
| Novo Nordisk | 15 | $270 |
| AbbVie | 6 | $247 |
| Pfizer | 10 | $172 |
| Almatica Pharma LLC | 8 | $134 |
| Corium, LLC | 6 | $93 |
| Lilly USA, LLC | 4 | $61 |
| Astellas Pharma US Inc | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $34 |
| GSK | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 2 | $28 |
| Novartis | 1 | $24 |
| Amgen | 1 | $22 |
| Bayer | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,009 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $45,803 |
| Omeprazole | 14 | $356 |
| Duloxetine Hcl | 14 | $282 |
| Gabapentin | 11 | $253 |
| Atorvastatin Calcium | 47 | $172 |
| Losartan Potassium | 23 | $172 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $164 |
| Lisinopril | 17 | $138 |
| Levothyroxine Sodium | 20 | $125 |
| Amlodipine Besylate | 18 | $103 |
| Furosemide | 11 | $49 |
| Hydrochlorothiazide | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $270 | $45,80335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Thomasville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.